In vivo study of famotidine tablet 40 mg

In vivo study of famotidine tablet 40 mg, iranian product compare to the brand one on healthy volunteers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230222057495N1

Enrollment

Registered

2023-03-05

Start date

2023-04-03

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention group: The study consists of two phases (taking a famotidine 40 mg tablet orally at each study time, for a total of 2 times) with a one-week washout period (when the drug is completely ou

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 50 years Non smoking BMI below 30 kg/m2

Exclusion criteria

Exclusion criteria: Blood pressure below 90/60 or more than 140/90 mmHg Smoking person (more than 10 /day) Using any kinds of medicine, alcohol or opioids during 2 weeks before starting the study

Design outcomes

Primary

Measure	Time frame
Famotidine plasma concentrations. Timepoint: 0, 20 ? 40 ? 60 ? 80 ? 100 ? 120 ? 150 ? 180 ? 240 ? 300 ? 360? 420? 600 ? 720 minutes after dose. Method of measurement: By HPLC- UV analytical instrument.	—

Secondary

Measure	Time frame
. Timepoint: . Method of measurement: .;. Timepoint: . Method of measurement: .	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonireh Jalalipour

Nikazma Pars Alborz

info@naplab.ir+98 26 3731 8748

Outcome results